Cyclo Therapeutics, Inc.
CYTH · NASDAQ
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 89.9% | -39.2% | -35% | – |
| Cost of Goods Sold | $0 | $1 | $1 | $1 |
| Gross Profit | $0 | -$1 | -$1 | -$1 |
| % Margin | 92.8% | -656.4% | -313.2% | -181.5% |
| R&D Expenses | $5 | $3 | $3 | $4 |
| G&A Expenses | $2 | $1 | $2 | $1 |
| SG&A Expenses | $2 | $1 | $2 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $1 | -$0 | $1 | -$2 |
| Operating Expenses | $9 | $5 | $4 | $5 |
| Operating Income | -$8 | -$6 | -$5 | -$6 |
| % Margin | -3,546% | -4,578% | -2,523.7% | -1,812% |
| Other Income/Exp. Net | -$1 | -$0 | $1 | $0 |
| Pre-Tax Income | -$9 | -$6 | -$4 | -$6 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$9 | -$6 | -$4 | -$6 |
| % Margin | -3,778.4% | -4,858.7% | -2,145.3% | -1,812% |
| EPS | -0.31 | -0.21 | -0.15 | -0.23 |
| % Growth | -47.6% | -40% | 34.8% | – |
| EPS Diluted | -0.31 | -0.21 | -0.15 | -0.23 |
| Weighted Avg Shares Out | 29 | 29 | 29 | 25 |
| Weighted Avg Shares Out Dil | 29 | 29 | 29 | 25 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$8 | -$6 | -$5 | -$6 |
| % Margin | -3,545% | -4,576.2% | -2,522.6% | -1,810.4% |